EE05421B1 - Fulvestrandi formulatsioonid - Google Patents

Fulvestrandi formulatsioonid

Info

Publication number: EE05421B1
Authority: EE; Estonia
Prior art keywords: fulvestrant formulations; fulvestrant; formulations
Prior art date: 2000-01-10

Application number

EEP200200387A

Other languages

English (en)

Estonian (et)

Inventor

Raymond Evans John

Ursula Grundy Rosalind

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-01-10

Filing date

2001-01-08

Publication date

2011-06-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26243352&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE05421(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-01-08 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2003-10-15 Publication of EE200200387A publication Critical patent/EE200200387A/xx

2011-06-15 Publication of EE05421B1 publication Critical patent/EE05421B1/xx

Links

VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 title 1
238000009472 formulation Methods 0.000 title 1
229960002258 fulvestrant Drugs 0.000 title 1
239000000203 mixture Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Dermatology (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Steroid Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

EEP200200387A 2000-01-10 2001-01-08 Fulvestrandi formulatsioonid EE05421B1 (et)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB0000313.7A GB0000313D0 (en)	2000-01-10	2000-01-10	Formulation
GBGB0008837.7A GB0008837D0 (en)	2000-01-10	2000-04-12	Formulation
PCT/GB2001/000049 WO2001051056A1 (en)	2000-01-10	2001-01-08	Fulvestrant formulation

Publications (2)

Publication Number	Publication Date
EE200200387A EE200200387A (et)	2003-10-15
EE05421B1 true EE05421B1 (et)	2011-06-15

Family

ID=26243352

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP200200387A EE05421B1 (et)	2000-01-10	2001-01-08	Fulvestrandi formulatsioonid

Country Status (41)

Country	Link
US (5)	US20030125387A1 (it)
EP (4)	EP1669073A3 (it)
JP (3)	JP3713237B2 (it)
KR (1)	KR100802366B1 (it)
CN (1)	CN1222292C (it)
AR (1)	AR027510A1 (it)
AT (1)	ATE306928T1 (it)
AU (1)	AU762080B2 (it)
BE (1)	BE1013477A3 (it)
BG (1)	BG65776B1 (it)
BR (1)	BR0107445B1 (it)
CA (1)	CA2351004C (it)
CH (1)	CH696260A5 (it)
CO (1)	CO5280206A1 (it)
CY (1)	CY1116520T1 (it)
CZ (1)	CZ304689B6 (it)
DE (2)	DE60114145T3 (it)
DK (2)	DK1250138T4 (it)
EE (1)	EE05421B1 (it)
EG (1)	EG24074A (it)
ES (3)	ES2248272T5 (it)
FR (1)	FR2803516B1 (it)
GB (3)	GB0000313D0 (it)
HK (2)	HK1052884B (it)
HU (1)	HU230162B1 (it)
IL (2)	IL150230A0 (it)
IS (1)	IS2932B (it)
IT (2)	ITTO20010005A1 (it)
MX (1)	MXPA02006698A (it)
MY (1)	MY118583A (it)
NL (1)	NL1017075C2 (it)
NO (2)	NO336286B1 (it)
PL (1)	PL202525B1 (it)
PT (2)	PT2266573E (it)
RU (1)	RU2263507C9 (it)
SI (2)	SI2266573T1 (it)
SK (1)	SK287221B6 (it)
TW (1)	TWI259086B (it)
UA (1)	UA75879C2 (it)
WO (1)	WO2001051056A1 (it)
ZA (1)	ZA200204165B (it)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0000313D0 (en) *	2000-01-10	2000-03-01	Astrazeneca Uk Ltd	Formulation
GB0116620D0 (en) *	2001-07-07	2001-08-29	Astrazeneca Ab	Formulation
EP1406662A1 (en) *	2001-07-07	2004-04-14	AstraZeneca AB	Pharmaceutical formulation for the intramuscular administration of fulvestrant
MXPA04011624A (es)	2002-05-24	2005-03-07	Schering Corp	Anticuerpo neutralizante humano anti-igfr.
TW200404552A (en) *	2002-05-30	2004-04-01	Akzo Nobel Nv	Self administered contraception
US20050152858A1 (en) *	2003-07-11	2005-07-14	Isp Investments Inc.	Solubilizing agents for active or functional organic compounds
AR046639A1 (es) *	2003-11-21	2005-12-14	Schering Corp	Combinaciones terapeuticas de anticuerpo anti- igfr1
EP1623713A1 (en) *	2004-07-09	2006-02-08	Proskelia SAS	Cominations of pure anti-estrogen with aromatase inhibitors
CN101222926B (zh) *	2005-04-15	2013-07-17	默沙东公司	用于治疗或预防癌症的方法和组合物
SG165404A1 (en) *	2005-09-26	2010-10-28	Hospira Australia Pty Ltd	Fulvestrant formulation
RU2338538C1 (ru) *	2007-02-09	2008-11-20	Государственное учебно-научное учреждение Химический факультет Московского государственного университета им. М.В. Ломоносова	Антигипотензивное средство
JP2011514349A (ja) *	2008-03-07	2011-05-06	サイドース・エルエルシー	フルベストラント配合物
GB0807605D0 (en) *	2008-04-28	2008-06-04	Diurnal Ltd	Lipid composition
AU2014200332B2 (en) *	2008-04-28	2016-10-06	Diurnal Limited	Lipid composition
UA104147C2 (uk) *	2008-09-10	2014-01-10	Новартис Аг	Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
US20100317635A1 (en)	2009-06-16	2010-12-16	Endorecherche, Inc.	Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
EP3205648A1 (en)	2010-06-10	2017-08-16	Seragon Pharmaceuticals, Inc.	Estrogen receptor modulators and uses thereof
US8853423B2 (en)	2010-06-17	2014-10-07	Seragon Pharmaceuticals, Inc.	Indane estrogen receptor modulators and uses thereof
CA2811258C (en) *	2010-09-16	2019-10-15	Shimoda Biotech (Pty) Ltd	Fulvestrant compositions and methods of use
CA2836831C (en) *	2011-05-20	2015-06-02	Capital, Business Y Gestion De Finanzas S.L.	Pharmaceutical composition
CN102391341B (zh) *	2011-08-09	2013-05-22	福建省微生物研究所	制备6,7-脱氢-17β-烃酰氧基诺龙的方法
CN103070871B (zh) *	2011-10-26	2015-04-15	正大天晴药业集团股份有限公司	一种氟维司群的药物组合物
EP2782584B1 (en)	2011-11-23	2021-06-09	TherapeuticsMD, Inc.	Natural combination hormone replacement formulations and therapies
US9301920B2 (en)	2012-06-18	2016-04-05	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
EP2791132A4 (en)	2011-12-14	2015-08-05	Seragon Pharmaceuticals Inc	ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
BR112014014767A2 (pt)	2011-12-16	2017-06-13	Olema Pharmaceuticals Inc	novos compostos de benzopirano, composições e usos dos mesmos
CN102600073B (zh) *	2012-03-31	2014-01-01	莱普德制药有限公司	以乳酸酯为基础的氟维司群或其衍生物油性制剂及其制备方法
CN102600064A (zh) *	2012-03-31	2012-07-25	西安力邦制药有限公司	氟维司群或其衍生物缓释制剂及其制备方法
CA2869377C (en) *	2012-04-09	2022-11-08	Scidose, Llc	Fulvestrant formulations
US11179468B2 (en)	2012-04-09	2021-11-23	Eagle Pharmaceuticals, Inc.	Fulvestrant formulations
US10806697B2 (en)	2012-12-21	2020-10-20	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en)	2012-06-18	2015-07-16	Therapeuticsmd, Inc.	Progesterone formulations having a desirable pk profile
US20130338122A1 (en)	2012-06-18	2013-12-19	Therapeuticsmd, Inc.	Transdermal hormone replacement therapies
US10806740B2 (en)	2012-06-18	2020-10-20	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US11266661B2 (en)	2012-12-21	2022-03-08	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en)	2012-12-21	2020-02-25	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en)	2012-12-21	2019-11-12	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en)	2012-12-21	2020-01-21	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en)	2012-12-21	2022-02-15	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en)	2012-12-21	2015-11-10	Therapeuticsmd, Inc.	Soluble estradiol capsule for vaginal insertion
US20160060288A1 (en)	2013-04-18	2016-03-03	Xi'anlibang Pharmaceutical Technology Co., Ltd.	Ester derivatives of 7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-estra-1,3,5(10)-triene-3,17beta-diol having anticancer activity and preparation method thereof
WO2014195032A1 (en)	2013-06-07	2014-12-11	Medical Prognosis Institute A/S	Methods and devices for predicting treatment efficacy of fulvestrant in cancer patients
WO2014203129A1 (en)	2013-06-19	2014-12-24	Olema Pharmaceuticals, Inc.	Combinations of benzopyran compounds, compositions and uses thereof
WO2014203132A1 (en)	2013-06-19	2014-12-24	Olema Pharmaceuticals, Inc.	Substituted benzopyran compounds, compositions and uses thereof
CN104337761B (zh) *	2013-08-07	2019-03-26	江苏豪森药业集团有限公司	氟维司群药物组合物
WO2015033302A2 (en) *	2013-09-06	2015-03-12	Salah Uddin Ahmed	Fulvestrant compositions
US9271990B2 (en)	2014-02-14	2016-03-01	Fresenius Kabi Usa, Llc	Fulvestrant formulations
SG11201607334YA (en)	2014-03-13	2016-10-28	Hoffmann La Roche	Therapeutic combinations with estrogen receptor modulators
AR100562A1 (es)	2014-05-22	2016-10-12	Therapeuticsmd Inc	Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
KR20170040209A (ko)	2014-07-29	2017-04-12	쎄러퓨틱스엠디, 인코퍼레이티드	경피 크림
TWI784255B (zh)	2014-12-18	2022-11-21	瑞士商赫孚孟拉羅股份公司	四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途
US10328087B2 (en)	2015-07-23	2019-06-25	Therapeuticsmd, Inc.	Formulations for solubilizing hormones
WO2017059139A1 (en)	2015-10-01	2017-04-06	Olema Pharmaceuticals, Inc.	TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS
CN108430454A (zh)	2015-10-13	2018-08-21	西弥斯医疗有限公司	氟维司群组合物
DK3386500T3 (da)	2015-12-09	2022-12-12	Univ Illinois	Benzothiophen-baserede selektive østrogenreceptor ned-regulatorer
KR20180126582A (ko)	2016-04-01	2018-11-27	쎄러퓨틱스엠디, 인코퍼레이티드	스테로이드 호르몬 약제학적 조성물
WO2017173044A1 (en)	2016-04-01	2017-10-05	Therapeuticsmd Inc.	Steroid hormone compositions in medium chain oils
EP3441073B1 (en)	2016-04-06	2022-02-23	FUJIFILM Corporation	Medicinal composition comprising fulvestrant
EP3440067B1 (en)	2016-04-08	2021-05-26	F. Hoffmann-La Roche AG	Tetrahydroisoquinoline estrogen receptor modulators and uses thereof
US11590077B2 (en)	2016-05-06	2023-02-28	Eagle Pharmaceuticals, Inc.	Fulvestrant formulations and methods of their use
IL285928B2 (en) *	2016-05-06	2025-06-01	Eagle Pharmaceuticals Inc	Fulvestrant formulations and methods of their use
CN109152785B (zh)	2016-05-31	2021-02-09	富士胶片株式会社	医药组合物
US20180002344A1 (en)	2016-06-16	2018-01-04	Genentech, Inc.	Heteroaryl estrogen receptor modulators and uses thereof
CN109311876B (zh) *	2016-06-16	2022-05-03	豪夫迈·罗氏有限公司	杂芳基雌激素受体调节剂及其用途
CN109843882A (zh)	2016-06-16	2019-06-04	豪夫迈·罗氏有限公司	四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
CN107789320B (zh) *	2016-08-31	2021-06-22	鲁南制药集团股份有限公司	一种氟维司群缓释注射液及其制备工艺
EP3681491A4 (en)	2017-09-11	2021-06-30	Atossa Therapeutics, Inc.	PROCESS FOR MANUFACTURING AND USE OF ENDOXIFES
BR112020009141A2 (pt) *	2017-11-08	2020-10-27	Eagle Pharmaceuticals, Inc.	método para tratar câncer de mama num indivíduo
MX2020004756A (es)	2017-11-16	2020-08-20	Novartis Ag	Terapias de combinacion.
WO2019151353A1 (ja) *	2018-01-31	2019-08-08	富士フイルム株式会社	注射用製剤の製造方法
RU2684330C1 (ru) *	2018-02-02	2019-04-08	Закрытое Акционерное Общество "Биокад"	Композиции фулвестранта
JP7384903B2 (ja)	2018-05-24	2023-11-21	ケーアイファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー	フルベストラントのプロドラッグ
AR116109A1 (es)	2018-07-10	2021-03-31	Novartis Ag	Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
CN111035613A (zh) *	2018-10-12	2020-04-21	江苏恒瑞医药股份有限公司	一种包含氟维司群的可注射的药物组合物及其制备方法
EP3873462A4 (en)	2018-11-01	2022-08-03	Syros Pharmaceuticals, Inc.	CANCER TREATMENT METHODS IN BIOMARKER-IDENTIFIED PATIENTS WITH NON-COVALENT INHIBITORS OF CYCLINE-DEPENDENT KINASE 7 (CDK7)
AU2019402189B2 (en)	2018-12-20	2023-04-13	Novartis Ag	Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
CA3123519A1 (en)	2019-02-15	2020-08-20	Novartis Ag	Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EP3924054B1 (en)	2019-02-15	2025-04-02	Novartis AG	3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
AU2020279979A1 (en)	2019-05-20	2021-11-25	Les Laboratoires Servier	Mcl-1 inhibitor antibody-drug conjugates and methods of use
WO2021003433A1 (en)	2019-07-03	2021-01-07	Atossa Therapeutics, Inc.	Sustained release compositions of endoxifen
CA3144791A1 (en)	2019-07-07	2021-01-14	Olema Pharmaceuticals, Inc.	Regimens of estrogen receptor antagonists
RU2722988C1 (ru) *	2019-11-19	2020-06-05	федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации	Способ моделирования проканцерогенного действия фулвестранта на яичники потомства женского пола у лабораторных мышей
EP4074304A4 (en)	2019-12-11	2024-01-10	Shanghai Bocimed Pharmaceutical Co., Ltd.	PHARMACEUTICAL COMPOSITION OF FULVESTRANT, PREPARATION METHOD AND APPLICATION THEREOF
US20230057071A1 (en)	2019-12-20	2023-02-23	Novartis Ag	Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
US11633405B2 (en)	2020-02-07	2023-04-25	Therapeuticsmd, Inc.	Steroid hormone pharmaceutical formulations
EP4168007A1 (en)	2020-06-23	2023-04-26	Novartis AG	Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
EP4188549A1 (en)	2020-08-03	2023-06-07	Novartis AG	Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
MX2023006010A (es)	2020-11-24	2023-06-08	Novartis Ag	Anticuerpos anti-cd48, conjugados de anticuerpo-farmaco, y usos de los mismos.
JP2023553808A (ja)	2020-11-24	2023-12-26	ノバルティスアーゲー	Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法
JP2024505562A (ja)	2021-02-02	2024-02-06	レスラボラトイレスセルビエル	選択的ｂｃｌ－ｘｌｐｒｏｔａｃ化合物及び使用の方法
TW202304979A (zh)	2021-04-07	2023-02-01	瑞士商諾華公司	抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es)	2021-05-18	2023-08-23	Novartis Ag	Terapias de combinación
WO2023121232A1 (ko) *	2021-12-20	2023-06-29	주식회사 삼양홀딩스	용해도가 개선된 풀베스트란트의 약학 조성물 및 그 제조 방법
EP4525925A1 (en)	2022-05-20	2025-03-26	Novartis AG	Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
CN119562832A (zh)	2022-05-20	2025-03-04	诺华股份有限公司	Met bcl-xl抑制剂抗体-药物缀合物及其使用方法
EP4676540A1 (en)	2023-03-10	2026-01-14	Novartis AG	Panras inhibitor antibody-drug conjugates and methods of use thereof
UY40985A (es)	2023-11-22	2025-06-30	Servier Lab	Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos
WO2025215536A1 (en)	2024-04-10	2025-10-16	Novartis Ag	Macrocyclic panras inhibitors for the treatment of cancer

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB817241A (en)	1957-08-21	1959-07-29	Vismara Francesco Spa	Oily solutions for parenteral administration containing adreno-cortical hormones
FR6241E (fr)	1905-04-19	1906-10-10	Ktiengesellschaft	Système de refroidissement du piston des moteurs à explosions et des compresseurs
DE947335C (de)	1954-10-19	1956-08-16	Schering Ag	Verfahren zur Herstellung stabiler oeliger Loesungen von Oestron
US2983649A (en)	1957-10-15	1961-05-09	Francesco Vismara Societa Per	Ricinoleic acid ester solutions of adreno-cortical hormones
GB1060632A (en) *	1962-09-11	1967-03-08	Olin Mathieson	Steroid compositions
US3164520A (en) *	1962-10-29	1965-01-05	Olin Mathieson	Injectable steroid compositions containing at least 75% benzyl benzoate
JPS4327327Y1 (it)	1965-01-07	1968-11-12
NL151903B (nl)	1965-03-24	1977-01-17	Schering Ag	Werkwijze ter bereiding van een injectievloeistof door een steroid op te lossen in een mengsel van ricinusolie en benzylbenzoaat.
USRE28690E (en) *	1965-05-05	1976-01-20	Schering Aktiengesellschaft	17α-Ethinyl-18-methyl-19-nortestosterone esters
GB1207571A (en) *	1967-01-13	1970-10-07	Takeda Chemical Industries Ltd	Injectable composition
SU549118A1 (ru)	1973-04-02	1977-03-05		Способ синхронизации половой охоты у циклирующих свиноматок
SU676284A1 (ru)	1975-06-26	1979-07-30	Научно-Исследовательский Институт Животноводства	Способ синхронизации половой охоты у самок домашних животных
DE2548413A1 (de)	1975-10-27	1977-04-28	Schering Ag	Depotpraeparate in oeliger ungesaettigter loesung zur intramuskulaeren injektion
US4048309A (en)	1976-02-24	1977-09-13	E. R. Squibb & Sons, Inc.	Topical steroid ointment formulations
US4048310A (en)	1976-02-24	1977-09-13	E. R. Squibb & Sons, Inc.	Topical steroid formulation in form of lotion or cream
NL7711916A (nl) *	1977-10-29	1979-05-02	Akzo Nv	Werkwijze ter bereiding van sterk geconcen- treerde farmaceutische preparaten van steroiden.
FI65914C (fi) *	1978-03-07	1984-08-10	Sandoz Ag	Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a
GB8327256D0 (en)	1983-10-12	1983-11-16	Ici Plc	Steroid derivatives
DE3708942A1 (de)	1987-03-18	1988-09-29	Schering Ag	19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
EP0310542B1 (de) *	1987-10-01	1994-06-08	Schering Aktiengesellschaft	Antigestagen- und antiöstrogenwirksame Verbindungen zur Behandlung hormonabhängiger Tumoren
DE3733478A1 (de)	1987-10-01	1989-04-13	Schering Ag	Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore
GB8813353D0 (en)	1988-06-06	1988-07-13	Ici Plc	Therapeutic product
JPH04327327A (ja)	1991-04-25	1992-11-16	Toyoda Gosei Co Ltd	スリーブとホースの加締め用ダイス
CN1102095A (zh)	1993-10-30	1995-05-03	浙江医科大学	长效雄激素类制剂——十一酸睾丸注射液
IL111991A (en)	1994-01-28	2000-07-26	Abbott Lab	Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
ZA9510926B (en) *	1994-12-23	1996-07-03	Schering Ag	Compounds with progesterone-antagonistic and antiestrogenic action to be used together for female contraception
US20010006963A1 (en)	1995-03-16	2001-07-05	Ursula Lachnit-Fixson	Once-a-month injection as a depot contraceptive and for hormone replacement therapy for perimenopausal and premenopausal women
DE19510861A1 (de)	1995-03-16	1996-09-19	Schering Ag	Einmonatsspritze als Depot-Kontrazeptivum und für die Hormonersatztherapie für peri- und praemenopausale Frauen
EP0760237A1 (en)	1995-08-30	1997-03-05	Cipla Limited	Oil-in-water microemulsions
GB9525194D0 (en) *	1995-12-12	1996-02-07	Zeneca Ltd	Pharmaceutical composition
JPH09208496A (ja) *	1996-01-30	1997-08-12	Takeda Chem Ind Ltd	Ｌｈ−ｒｈ拮抗物質含有組成物
DE19613972A1 (de)	1996-04-09	1997-10-16	Bayer Ag	Injektionsformulierungen von Avermectinen und Milbemycinen auf Basis von Rizinusöl
GB9608719D0 (en)	1996-04-26	1996-07-03	Scherer Ltd R P	Pharmaceutical compositions
JPH10203982A (ja) *	1996-07-05	1998-08-04	Takeda Chem Ind Ltd	視機能障害の予防・治療剤
US5952338A (en)	1996-07-05	1999-09-14	Takeda Chemical Industries, Ltd.	Agent for prophylaxis and treatment of disturbance of visual function
DE19635525A1 (de) *	1996-08-20	1998-02-26	Schering Ag	7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
DE19638045A1 (de)	1996-09-18	1998-03-19	Bayer Ag	Injektionsformulierungen von Avermectinen und Milbemycinen
JPH10152438A (ja) *	1996-11-22	1998-06-09	Takeda Chem Ind Ltd	１−アザキサントン誘導体またはその塩の安定化方法および１−アザキサントン誘導体含有組成物
JPH11158200A (ja) *	1997-09-26	1999-06-15	Takeda Chem Ind Ltd	ヒト成長ホルモン・亜鉛複合体及びその用途
US6191107B1 (en)	1997-09-26	2001-02-20	Takeda Chemical Industries, Ltd.	Complex of human growth hormone and zinc
ATE249206T1 (de)	1997-12-03	2003-09-15	Merck & Co Inc	Langwirkende, injizierbare, formulierungen enthaltend rizinusöl
EP1169021B1 (en)	1999-04-01	2009-09-16	Hana Biosciences, Inc.	Compositions and methods for treating lymphoma
GB0000313D0 (en)	2000-01-10	2000-03-01	Astrazeneca Uk Ltd	Formulation
JP4327327B2 (ja)	2000-04-03	2009-09-09	ロボテック株式会社	固定スプレー揺動装置
EP1406662A1 (en)	2001-07-07	2004-04-14	AstraZeneca AB	Pharmaceutical formulation for the intramuscular administration of fulvestrant
GB0912999D0 (en)	2009-07-27	2009-09-02	Astrazeneca Ab	Method-803

2000
- 2000-01-10 GB GBGB0000313.7A patent/GB0000313D0/en not_active Ceased
- 2000-04-12 GB GBGB0008837.7A patent/GB0008837D0/en not_active Ceased
2001
- 2001-01-08 CZ CZ2002-2384A patent/CZ304689B6/cs not_active IP Right Cessation
- 2001-01-08 AU AU23863/01A patent/AU762080B2/en not_active Expired
- 2001-01-08 SI SI200131044T patent/SI2266573T1/sl unknown
- 2001-01-08 KR KR1020027008855A patent/KR100802366B1/ko not_active Expired - Lifetime
- 2001-01-08 MX MXPA02006698A patent/MXPA02006698A/es active IP Right Grant
- 2001-01-08 CA CA002351004A patent/CA2351004C/en not_active Expired - Fee Related
- 2001-01-08 ES ES01900186.6T patent/ES2248272T5/es not_active Expired - Lifetime
- 2001-01-08 ES ES10180667.7T patent/ES2543384T3/es not_active Expired - Lifetime
- 2001-01-08 EG EG20010017A patent/EG24074A/xx active
- 2001-01-08 WO PCT/GB2001/000049 patent/WO2001051056A1/en not_active Ceased
- 2001-01-08 SI SI200130446T patent/SI1250138T2/sl unknown
- 2001-01-08 HK HK03105241.3A patent/HK1052884B/zh not_active IP Right Cessation
- 2001-01-08 DE DE60114145.8T patent/DE60114145T3/de not_active Expired - Lifetime
- 2001-01-08 EP EP05016921A patent/EP1669073A3/en not_active Withdrawn
- 2001-01-08 DK DK01900186.6T patent/DK1250138T4/en active
- 2001-01-08 AT AT01900186T patent/ATE306928T1/de active
- 2001-01-08 RU RU2002121507A patent/RU2263507C9/ru active
- 2001-01-08 HU HU0204137A patent/HU230162B1/hu not_active IP Right Cessation
- 2001-01-08 JP JP2001551480A patent/JP3713237B2/ja not_active Expired - Lifetime
- 2001-01-08 GB GB0100407A patent/GB2359254B/en not_active Expired - Lifetime
- 2001-01-08 PT PT101806677T patent/PT2266573E/pt unknown
- 2001-01-08 IL IL15023001A patent/IL150230A0/xx active IP Right Grant
- 2001-01-08 EE EEP200200387A patent/EE05421B1/xx unknown
- 2001-01-08 CN CNB018035469A patent/CN1222292C/zh not_active Ceased
- 2001-01-08 HK HK03101532.0A patent/HK1049286B/en not_active IP Right Cessation
- 2001-01-08 EP EP01900186.6A patent/EP1250138B2/en not_active Expired - Lifetime
- 2001-01-08 BR BRPI0107445-8A patent/BR0107445B1/pt active IP Right Grant
- 2001-01-08 DK DK10180667.7T patent/DK2266573T3/en active
- 2001-01-08 US US10/169,777 patent/US20030125387A1/en not_active Abandoned
- 2001-01-08 PL PL356030A patent/PL202525B1/pl unknown
- 2001-01-08 EP EP10180661.0A patent/EP2286818B1/en not_active Expired - Lifetime
- 2001-01-08 EP EP10180667.7A patent/EP2266573B1/en not_active Expired - Lifetime
- 2001-01-08 SK SK984-2002A patent/SK287221B6/sk not_active IP Right Cessation
- 2001-01-09 BE BE2001/0021A patent/BE1013477A3/fr not_active IP Right Cessation
- 2001-01-09 IT IT000005A patent/ITTO20010005A1/it unknown
- 2001-01-09 PT PT102548A patent/PT102548A/pt not_active Application Discontinuation
- 2001-01-09 US US09/756,291 patent/US6774122B2/en not_active Expired - Lifetime
- 2001-01-10 FR FR0100248A patent/FR2803516B1/fr not_active Expired - Lifetime
- 2001-01-10 DE DE10100779A patent/DE10100779A1/de not_active Ceased
- 2001-01-10 IT IT2001TO000008A patent/ITTO20010008A1/it unknown
- 2001-01-10 AR ARP010100100A patent/AR027510A1/es not_active Application Discontinuation
- 2001-01-10 NL NL1017075A patent/NL1017075C2/nl not_active IP Right Cessation
- 2001-01-10 TW TW090100514A patent/TWI259086B/zh not_active IP Right Cessation
- 2001-01-10 CH CH00029/01A patent/CH696260A5/de not_active IP Right Cessation
- 2001-01-10 MY MYPI20010107A patent/MY118583A/en unknown
- 2001-01-10 ES ES200100057A patent/ES2186517B2/es not_active Expired - Fee Related
- 2001-01-10 CO CO01001317A patent/CO5280206A1/es not_active Application Discontinuation
- 2001-08-01 UA UA2002086628A patent/UA75879C2/uk unknown
2002
- 2002-05-24 ZA ZA200204165A patent/ZA200204165B/xx unknown
- 2002-06-13 IL IL150230A patent/IL150230A/en unknown
- 2002-06-18 BG BG106833A patent/BG65776B1/bg unknown
- 2002-07-03 NO NO20023227A patent/NO336286B1/no not_active IP Right Cessation
- 2002-07-03 IS IS6454A patent/IS2932B/is unknown
2003
- 2003-10-23 JP JP2003362875A patent/JP2004107353A/ja not_active Ceased
2004
- 2004-06-22 US US10/872,784 patent/US7456160B2/en not_active Expired - Lifetime
2008
- 2008-10-15 US US12/285,887 patent/US8329680B2/en not_active Expired - Fee Related
2011
- 2011-06-20 JP JP2011135962A patent/JP2011190275A/ja active Pending
2012
- 2012-09-04 US US13/602,667 patent/US8466139B2/en not_active Expired - Fee Related
2015
- 2015-06-08 NO NO20150741A patent/NO337329B1/no not_active IP Right Cessation
- 2015-07-22 CY CY20151100648T patent/CY1116520T1/el unknown

Also Published As

Publication number	Publication date
CZ304689B6 (cs)	2014-09-03
NO20023227D0 (no)	2002-07-03
DK2266573T3 (en)	2015-07-20
ES2186517A1 (es)	2003-05-01
RU2263507C9 (ru)	2020-07-28
AR027510A1 (es)	2003-04-02
HK1049286A1 (en)	2003-05-09
NL1017075C2 (nl)	2001-09-25
HK1052884B (zh)	2006-07-14
GB2359254A (en)	2001-08-22
US7456160B2 (en)	2008-11-25
US8466139B2 (en)	2013-06-18
CH696260A5 (de)	2007-03-15
EP1669073A2 (en)	2006-06-14
CZ20022384A3 (cs)	2002-09-11
SK9842002A3 (en)	2003-05-02
NO336286B1 (no)	2015-07-13
JP3713237B2 (ja)	2005-11-09
PL202525B1 (pl)	2009-07-31
EP2286818A1 (en)	2011-02-23
CN1222292C (zh)	2005-10-12
EP1250138A1 (en)	2002-10-23
HK1049286B (en)	2006-04-07
BE1013477A3 (fr)	2002-02-05
DK1250138T3 (da)	2006-01-23
BR0107445B1 (pt)	2012-10-30
GB0008837D0 (en)	2000-05-31
ES2543384T3 (es)	2015-08-18
IL150230A0 (en)	2002-12-01
US20030125387A1 (en)	2003-07-03
GB2359254B (en)	2002-06-19
GB0000313D0 (en)	2000-03-01
MXPA02006698A (es)	2002-09-30
MY118583A (en)	2004-12-31
CO5280206A1 (es)	2003-05-30
EP1250138B2 (en)	2015-07-08
IS2932B (is)	2015-12-15
HK1052884A1 (en)	2003-10-03
JP2003519659A (ja)	2003-06-24
PT2266573E (pt)	2015-07-28
EP1250138B1 (en)	2005-10-19
WO2001051056A1 (en)	2001-07-19
SI1250138T1 (sl)	2006-02-28
CY1116520T1 (el)	2017-03-15
HUP0204137A2 (hu)	2003-04-28
ITTO20010008A1 (it)	2002-07-10
ES2186517B2 (es)	2004-03-16
KR100802366B1 (ko)	2008-02-13
ES2248272T3 (es)	2006-03-16
IL150230A (en)	2006-10-31
JP2011190275A (ja)	2011-09-29
SK287221B6 (sk)	2010-03-08
NO20150741L (no)	2002-07-03
NO337329B1 (no)	2016-03-14
FR2803516B1 (fr)	2003-03-28
TWI259086B (en)	2006-08-01
US20050043285A1 (en)	2005-02-24
HK1150021A1 (en)	2011-10-28
CN1394141A (zh)	2003-01-29
ES2248272T5 (es)	2015-08-19
EP2266573A1 (en)	2010-12-29
UA75879C2 (en)	2006-06-15
EP2286818B1 (en)	2020-03-18
US20120329766A1 (en)	2012-12-27
EP2266573B1 (en)	2015-06-17
DE60114145D1 (de)	2006-03-02
RU2002121507A (ru)	2004-03-20
CA2351004C (en)	2003-02-18
AU2386301A (en)	2001-07-24
US20010020016A1 (en)	2001-09-06
DK1250138T4 (en)	2015-07-27
KR20020073499A (ko)	2002-09-26
ITTO20010005A0 (it)	2001-01-09
ITTO20010008A0 (it)	2001-01-10
ZA200204165B (en)	2003-10-29
GB0100407D0 (en)	2001-02-21
SI1250138T2 (sl)	2015-09-30
RU2263507C2 (ru)	2005-11-10
FR2803516A1 (fr)	2001-07-13
NO20023227L (no)	2002-07-03
DE10100779A1 (de)	2001-07-26
CA2351004A1 (en)	2001-07-10
ATE306928T1 (de)	2005-11-15
IS6454A (is)	2002-07-03
US20100152149A1 (en)	2010-06-17
ITTO20010005A1 (it)	2001-07-11
HUP0204137A3 (en)	2005-03-29
BG65776B1 (bg)	2009-11-30
US6774122B2 (en)	2004-08-10
JP2004107353A (ja)	2004-04-08
EE200200387A (et)	2003-10-15
BG106833A (en)	2003-03-31
EP1669073A3 (en)	2008-03-19
BR0107445A (pt)	2002-09-17
SI2266573T1 (sl)	2015-08-31
PT102548A (pt)	2001-07-31
EG24074A (en)	2008-05-11
NL1017075A1 (nl)	2001-07-11
US8329680B2 (en)	2012-12-11
HU230162B1 (hu)	2015-09-28
AU762080B2 (en)	2003-06-19
DE60114145T3 (de)	2015-09-17
DE60114145T2 (de)	2006-07-13
PL356030A1 (en)	2004-06-14

Publication	Publication Date	Title
EE200200387A (et)	2003-10-15	Fulvestrandi formulatsioonid
DK1317177T3 (da)	2004-12-20	Desinficerende formuleringer
ATE303787T1 (de)	2005-09-15	Schergelzusammensetzungen
AR028197A1 (es)	2003-04-30	Composiciones antitranspirantes
ATE290000T1 (de)	2005-03-15	Muscarinagonisten
ATE252099T1 (de)	2003-11-15	Biarylcarboxamide
ATA2932001A (de)	2004-11-15	Schneefräse
NO20031869D0 (no)	2003-04-25	Antiinflammatoriske midler
DE50101916D1 (de)	2004-05-13	Flüssige formulierungen
ATE369830T1 (de)	2007-09-15	Schweisshemmende zusammensetzungen
ATE262530T1 (de)	2004-04-15	Indolochinazolinone
IS6398A (is)	2002-05-27	Lyfjablöndur
ATE314049T1 (de)	2006-01-15	Schweisshemmende zusammensetzungen
NO20030276L (no)	2003-03-18	Fremgangsmåte
ATE298751T1 (de)	2005-07-15	7-oxopyridoryrimidine
AR028336A1 (es)	2003-05-07	4-hidroxi-tetrahidropiridonas fenilsubstituidas
DE60116858D1 (de)	2006-04-13	Zusammensetzung
ATE509008T1 (de)	2011-05-15	Sulfonylguanidine
AR028061A1 (es)	2003-04-23	2-enamino-cetonitrilos fenil-substituidos
ATE268116T1 (de)	2004-06-15	Mesotrion-formulierungen
ATE476423T1 (de)	2010-08-15	Benzoylpyridazine
AR027982A1 (es)	2003-04-23	Aril- y heteroarilsulfonatos
DE60107312D1 (de)	2004-12-30	Feste Zusammensetzung
FI20002525A7 (fi)	2002-05-18	Tulehduksenvastaisia aineita
ATE284887T1 (de)	2005-01-15	Thienopyrrolidinone